Independent Report – Eli Lilly’s Orforglipron Pill has shown remarkable benefits for patients with type 2 diabetes. The once-daily pill reduced body weight by an average of 10.5% in participants on the highest dose. It also helped 75% of patients bring their A1C level to 6.5% or lower, which is below the American Diabetes Association’s recommended target of 7% for most adults.
Lilly’s Orforglipron Pill is a small-molecule treatment, making it easier to manufacture and distribute than injectable therapies like Lilly’s Zepbound and Novo Nordisk’s Wegovy. These injectables are peptide-based drugs that mimic the GLP-1 hormone to control appetite. In contrast, Lilly’s Orforglipron Pill can be produced on a massive scale. According to Kenneth Custer, president of Lilly’s cardiometabolic health division. The pill could expand access to treatment for millions of patients worldwide.
The new results come from a 72-week clinical trial that included more than 1,600 adults who were overweight or obese and living with type 2 diabetes. Participants who received the highest 36-milligram dose of orforglipron lost on average about 23 pounds, equal to 10.5% of their body weight. This compared with a 2.2% reduction for the placebo group, meeting the main goal of the study. Even at the lowest tested dose of 6 milligrams, patients lost an average of 5.5% of their weight.
Also Read : US Lawmakers, Unions Challenge Automated Railroad Inspections
Weight loss is typically harder to achieve for people with type 2 diabetes compared with those without the condition. Custer noted that this makes the results especially encouraging, as it demonstrates that the pill can be effective even for patients who usually struggle to shed weight. With this data, Lilly now has the full clinical evidence package required to begin regulatory submissions for orforglipron across different markets.
When asked whether the company would seek a priority review voucher from the U.S. Food and Drug Administration, Custer explained that all options remain open. A voucher would shorten the agency’s review period from the standard ten months to six months, allowing the drug to potentially reach patients sooner.
Earlier late-stage studies of orforglipron in adults without diabetes showed even greater average weight loss, reaching 12.4% over a similar treatment period. Analysts had hoped the pill might match or surpass Wegovy, which in 2021 achieved a 14.9% weight reduction after 68 weeks. While orforglipron fell slightly short of that benchmark, it still showed meaningful effectiveness, especially given its convenient pill format.
However, side effects were common, as with other drugs in this class. In the latest study, 36.4% of high-dose participants reported nausea, and 23.1% experienced vomiting. This compared with much lower rates among placebo patients, at 8.4% and 3.8% respectively. Around 10% of participants in the high-dose group discontinued treatment due to these side effects. Still, no serious liver-related safety issues were observed. These findings were consistent with earlier studies, where nausea and vomiting were also the most frequent concerns.
Despite these challenges, Lilly emphasized additional benefits seen with orforglipron. The trial showed improvements in heart-related risk factors, including reductions in cholesterol, triglycerides, and blood pressure across all dosing levels. These results mirror other GLP-1–based therapies that not only aid weight loss but also protect cardiovascular health. Novo Nordisk’s Wegovy has already been approved to reduce the risk of major heart events. Meanwhile, Lilly’s Mounjaro, which contains the same key ingredient as Zepbound, has also shown strong heart-protective data.
Competition in the weight-loss market is intensifying. Analysts predict the global market for obesity treatments could generate as much as $150 billion per year by the early 2030s. At present, Wegovy and Zepbound dominate sales, but orforglipron could become a major alternative due to its oral format. Novo is also awaiting FDA review for a high-dose oral version of Wegovy. Which delivered 15% weight loss in a late-stage trial.
The future of obesity and diabetes treatment is shifting toward a wide range of options. From injectable therapies to oral medications. Lilly believes orforglipron will play a central role in that landscape by offering patients an effective, scalable, and easier-to-use alternative. If approved, it could help millions of people worldwide manage both their weight and their long-term health.
Also Read : Trump Removes Fed Governor Lisa Cook over Alleged False Mortgage Statements
